Acute Cardiac Dysfunction in Critical Illnes

NCT ID: NCT05860504

Last Updated: 2023-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

592 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-29

Study Completion Date

2026-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall aim of the study is to establish the clinical importance of cardiac dysfunction, by estimating its incidence and impact on short- and long-term outcomes, in a mixed population of critically ill patients with multi-organ failure. Pathogenesis of cardiac dysfunction in critical illness and key molecules linked to this will be explored.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During critical illness, the heart is exposed to extreme external stressors, which may contribute to heart failure. There is a lack of knowledge of what happens to the heart over the course of critical illness. The few studies available suggest that LV dysfunction is common in critical illness, with a prevalence of 10-30%. Notably, LV regional hypokinesia is a frequent pattern of LV dysfunction among these patients and is associated with a higher risk of death.

LV regional hypokinesia during critical illness may have several possible aetiologies, including ischemic, inflammatory or other/mixed processes. Of these, acute coronary artery obstruction is probably most important. Patients with sepsis, for example, and acute ST elevation myocardial infarction have twice the risk of death. Type II myocardial infarction can also lead to LV dysfunction due to insufficient coronary artery flow e.g., from tachycardia, hypotension and hypoxia, resulting in myocardial ischemia. In the absence of CAD, LV regional hypokinesia could also result from myocardial inflammation secondary to systemic inflammatory response, direct toxic effects of cytokines or pathogenic infiltration. Another possible aetiology is Takotsubo syndrome, an acute cardiac condition characterised by reversible regional hypokinesia, usually in the apical portion of the LV. The current paradigm suggests that Takotsubo syndrome is triggered by the overstimulation of the myocardium by catecholamines and is closely correlated to events involving severe emotional or physical stress. Cardiac dysfunction in critical illness is likely a phenotype of Takotsubo syndrome since patients in the ICU undergo extreme stress and are exposed to both endogenously-released and exogenously-administered catecholamines.

In critical illness, accurate diagnosis of LV dysfunction is challenging due to the similar clinical presentation of potential aetiologies. However, diagnosing the underlying aetiology of LV dysfunction is essential to provide appropriate treatment and optimise outcomes. CAD can be diagnosed with coronary angiography and cardiac computed tomography (CCT). In the absence of CAD, cMRI is useful. cMRI can differentiate between myocardial ischemia, and inflammation, as well as between an acute or past event.

In this study, patients are examined with echocardiography to identify those with cardiac dysfunction. In a sub-set of patients with LV dysfunction, patients will be examined with coronary CT (if no angiography performed) and cardiac MRI. Blood samples are collected for storage in biobank.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multi Organ Failure Left Ventricular Dysfunction Right Ventricular Dysfunction Tako Tsubo Cardiomyopathy Myocardial Infarction Cardiomyopathy, Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal left ventricular systolic function

Patients with normal echocardiographic systolic function, defined as having left ventricular ejection fraction ≥ 50% and no regional hypokinesia

Echocardiography

Intervention Type DIAGNOSTIC_TEST

All patients in the study will be examined with echocardiography

Left ventricular dysfunction

Patients with echocardiographic left ventricular systolic dysfunction, defines as having left ventricular ejection fraction \< 50% or left ventricular regional hypokinesia in at least two adjacent segments

Echocardiography

Intervention Type DIAGNOSTIC_TEST

All patients in the study will be examined with echocardiography

Cardiac magnetic resonance imaging

Intervention Type DIAGNOSTIC_TEST

Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI

Coronary CT

Intervention Type DIAGNOSTIC_TEST

Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Echocardiography

All patients in the study will be examined with echocardiography

Intervention Type DIAGNOSTIC_TEST

Cardiac magnetic resonance imaging

Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI

Intervention Type DIAGNOSTIC_TEST

Coronary CT

Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cMRI CCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged \> 18 years
2. Admitted to a participating ICU within 24 hours
3. Significant organ dysfunction involving at least two organ systems. This is defined as fulfilling both of the following:

* At least 4 points on the SOFA scale (Sequential Organ Failure Assessment scale)
* Having at least 1 point on the SOFA scale from at least two organ systems
4. Given informed consent from patient or permission to participate from next of kin

Exclusion Criteria

1. Echocardiographic examination not possible (e.g., pneumothorax, draping etc) or very low echocardiographic examination quality
2. Not being examined with echocardiography within 24 hours from inclusion
3. Retracted consent to participate
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sahlgrenska University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jonatan Oras

Associate professor/Senior consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sahgrensak University Hospital

Västra Frölunda, Please Select, Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jonatan Oras, MD, PhD

Role: CONTACT

+46313421000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jacob Holmqvist, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SCCCS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.